NIH Research Committee

Dear Colleagues,

We are writing again to ask you to change your recommendations on the use of COVID-19 Convalescent Plasma (CCP). We have sent you three prior letters urging changes in the NIH Research Committee recommendations. Each was acknowledged but none was answered.

We have learned from Janet Handal of TRAIPAG that on March 18, 2023, you wrote to her that ‘Our view remains that the available data are insufficient to make a clear recommendation for or against the use of high-titer CCP for the treatment of COVID-19 in hospitalized or nonhospitalized patients who are immunocompromised. We continue to note that some Panel members would use CCP to treat an immunocompromised patient with significant symptoms attributable to COVID-19 who is having an inadequate response to available therapies.’ We are deeply disappointed with this response.

Since our last letter to you in early December 2022 additional data showing the efficacy of CCP in immunocompromised patients has been published (1), including one randomized controlled trial (2). In addition, a group of physicians that includes signatories to this and prior letters has published guidance for the use of CCP in immunosuppressed patients (3). The FDA continues to support the use of CCP and has extended its Emergency Use Authorization until November 2023 in anticipation of the end of the COVID-19 emergency, 180 days after the end of the COVID-19 Public Health Emergency, during which time FDA plans to further revise the guidance, with any appropriate changes based on comments received and the Agency's experience with implementation (https://www.federalregister.gov/documents/2023/03/13/2023-05094/guidance-documents-related-to-coronavirus-disease-2019-covid-19)

We note that in addition to the FDA, the IDSA, AABB and ECIL-9 have each endorsed CCP in selected patient populations. In addition, we note publications from other countries that support the use of CCP for selected patient populations (4, 5).

Since our last letter to you all anti-SARS-CoV-2 monoclonal antibodies have been withdrawn, leaving CCP as the only virus-targeting antibody therapy available for our immunosuppressed patients. The neutral stance taken by the NIH Research Committee has led some institutions to balk at providing CCP to immunosuppressed patients. Hence, your position is not being received as neutral and may be leading to suboptimal care of vulnerable patients.

Although we are not privy to your discussions, we have strived to imagine your possible objections to recommending CCP, or at least to abandoning a neutral stance and list them below together with our responses.

1. The available efficacy data predates omicron. While true, the same consideration applies to Remdesivir and Paxlovid, which are recommended by the committee. We note that in the past the NIH Research Committee has recommended monoclonal antibodies on the strength of in vitro neutralizing data alone. Since CCP and monoclonal antibodies have the same active ingredient, it would be logically consistent to extend the recommendation to CCP.
2. CCP is a heterogenous product. Like all blood products, including platelets and packed red cell units, CCP is heterogeneous. But despite its heterogeneity, CCP can be standardized by antibody titer and the FDA has clear recommendations on what constitutes an authorized unit of CCP.
3. Hard to use and not available. We agree that the logistics of using CCP are more complex than administering monoclonal antibodies or oral antivirals. However, one can argue that administration of CCP, which can be performed in a single visit, is simpler than administering three days of outpatient intravenous remdesivir. In fact, the choice between CCP and remdesivir brings up an issue of equity. It is surely easier for economically disadvantaged patients to take off one day of work to receive a CCP infusion than to miss three days of work to get remdesivir infusions. CCP is readily available in the United States from the blood banking community and is currently being used to treat immunocompromised patients with COVID in many leading institutions in the United States including Einstein/Montefiore, Johns Hopkins, and the Mayo Clinic.
4. Early trials performed in very sick hospitalized patients failed to show benefit. Even a well-conducted RCT of an effective intervention will fail to show benefit when applied to the wrong population. The entire history of passive antibody therapy emphasizes the necessity of early administration before disease has reached an advanced stage. Nevertheless, some early studies administered CCP far too late to yield a benefit. This is evident in the data - if one aggregates the findings from 39 RCTs a clear statistically significant 9% reduction in mortality emerges. That effect increases to 35% when considering only early use with high titer plasma (6). Poorly designed trials should not drive public policy.
5. A higher benchmark is needed for CCP titer. Perhaps you want CCP used for therapy to be qualified at a higher antibody titer. We agree that the highest titer is best and today there are very high-quality units available from individuals who had both COVID-19 and vaccination. While 80-90% of donors qualify for CCP donation under current guidelines, CCP from 25 to 30% donors with the highest titers would be even more efficacious. If this is an issue for the committee, we urge you to make it clear. We are confident that the FDA would be receptive.

We urge you to reconsider your ‘neutral’ stance on CCP and to reword your recommendations to make them consistent with the available scientific evidence. We note in your message to Ms. Handel ‘that some Panel members would use CCP to treat an immunocompromised patient with significant symptoms attributable to COVID-19 who is having an inadequate response to available therapies’. We think that these panel members are correct in their judgement of CCP and that perhaps their view can be given greater prominence and visibility in your recommendation. In light of reports that CCP is being denied to some patients because of your neutral recommendation, abandoning this stance would help immunocompromised patients, and firmly align the actions of your committee with the time-honored dictum of ‘primum non nocere’.

Sincerely yours,

The COVID-19 Convalescent Plasma Project Leadership Group p(ccpp19.org)

Arturo Casadevall, MD, PhD, Chair COVID-19 Convalescent Plasma Project (ccpp19).

Chair, Department of Molecular Microbiology & Immunology

Bloomberg Distinguished Professor

Alfred and Jill Sommer Professor and Chair

Johns Hopkins School of Public Health

Brenda Grossman, MD

Professor, Pathology & Immunology
Professor of Medicine

Medical Director, Transfusion Medicine Services

Washington University School of Medicine

Jeffrey Henderson, MD, PhD

Associate Professor of Medicine and Molecular Microbiology

Division of Infectious Diseases

Washington University School of Medicine

Michael Joyner, MD

Caywood Professor of Anesthesiology

Vice Chair (Research) Department of Anesthesiology & Perioperative Medicine

Mayo Clinic

Nigel Paneth, MD

University Distinguished Professor, Emeritus

Departments of Epidemiology & Biostatistics and Pediatrics & Human Development

Michigan State University

Liise-anne Pirofski, MD

Selma and Dr. Jacques Mitrani Chair in Biomedical Research

Professor, Medicine, Microbiology, and Immunology

Chief, Division of Infectious Diseases

Albert Einstein College of Medicine and Montefiore Medical Center

Shmuel Shoham, MD

Professor

Department of Medicine

Johns Hopkins School of Medicine

(Views expressed here are those of the signatories)

Other Signatories

Lilian Abbo, MD, MBA, FIDSA

Associate Chief Medical Officer for Infectious Diseases

Jackson Health System

Professor of Clinical Infectious Diseases

University of Miami Miller School of Medicine

Matthew Abinante, DO, MPH

Chief Executive Officer

Ascada Research

Fullerton, CA

Peter Agre, MD

Bloomberg Distinguished Professor

Departments of Medicine and Microbiology and Immunology

Johns Hopkins University

(Nobel Prize in Chemistry 2005)

Enver Akalin MD, FAST, FASN

Medical Director, Kidney Transplant Program

Albert Einstein College of Medicine and Montefiore Medical Center

Barbara D. Alexander, MD, MHS, FIDSA

Vice Chief, Transplant Infectious Diseases

Director, Transplant ID Fellowship Program

Head, Clinical Mycology Laboratory

Professor of Medicine and Pathology

Duke University

(IDSA President 2021)

David Alland, MD

Professor and Chief, Division of Infectious Disease

Director, The Public Health Research Institute (PHRI)

Director, The Center for COVID-19 Response and Pandemic Preparedness (CCRP2)

Director, Rutgers Regional Bio-containment Laboratory (RBL)

Director, The Center for Emerging Pathogens (EP)

Rutgers University - New Jersey Medical School

David Andes, MD

William A. Craig Professor

Chief, Division of Infectious Diseases

Director, Wisconsin Antimicrobial Discovery and Development Center

Department of Medicine

Department of Medical Microbiology and Immunology

School of Medicine and Public Health and School of Pharmacy

University of Wisconsin-Madison

Shweta Anjan, MD

Assistant Professor of Clinical Medicine

Associate Program Director, Transplant Infectious Disease Fellowship

Division of Infectious Diseases

Transplant and Immunocompromised Host Service

Jackson Memorial Hospital

Miami Transplant Institute

University of Miami Miller School of Medicine

Lawrence J. Appel, MD, MPH

C. David Molina, M.D., M.P.H. Professor of Medicine with Joint

Appointments in Epidemiology, International Health and Nursing

Director, Welch Center for Prevention, Epidemiology,

and Clinical Research

Johns Hopkins Medical Institutions

Cesar A. Arias MD, MSc, PhD

John F. III and Ann H. Bookout Distinguished Chair

Professor and Chief, Division of Infectious Diseases, Houston Methodist Hospital

Professor of Medicine, Weill Cornell Medical College

Co-Director Center for Infectious Diseases

Houston Methodist Research Institute

Paul Auwaerter, MD

Clinical Director, Division of Infectious Diseases

Professor of Medicine

Johns Hopkins School of Medicine

(IDSA President, 2018)

Robin Avery, MD

Professor of Medicine, Division of Infectious Diseases

Transplant and Oncology Infectious Diseases Program

Johns Hopkins

Martin J. Blaser, M.D.

Henry Rutgers Chair of the Human Microbiome

Professor of Medicine and Pathology & Laboratory Medicine – RWJMS

Director, Center for Advanced Biotechnology and Medicine

Rutgers University

Editor, Principles and Practice of Infectious Diseases

(IDSA President 2006)

Katharine J Bar, MD

Assistant Professor of Medicine

Attending Physician, Infectious Diseases, Hospital of the University of Pennsylvania

Physician, International Travel Medicine Clinic, Perelman Center for Advanced Medicine

Director, Penn CFAR Viral and Molecular Core

University of Pennsylvania

Evan Bloch, MD

Associate Director, Transfusion Medicine Division

Associate Professor of Pathology

Johns Hopkins School of Medicine

Baltimore, MD

Robert Bonomo, MD

Professor of Medicine

Case Western Reserve University

Helen W. Boucher, MD FACP FIDSA

Dean and Professor of Medicine

Tufts University School of Medicine

Chief Academic Officer, Tufts Medicine

David R Boulware MD, MPH, CTropMed, FIDSA

Professor of Medicine

Infectious Disease & International Medicine

Department of Medicine | University of Minnesota

Anthony Bowen, MD, PhD

Division of Infectious Diseases

Columbia University Medical Center

Michael P. Busch, MD, PhD

Affiliate Investigator, and Professor of Laboratory Medicine

University of California, San Francisco

Edward Cachay, MD

Infectious Disease Specialist

Professor of Medicine

UC San Antonio Health

Stephen B. Calderwood, M. D.

Morton N. Swartz, MD Distinguished Academy Professor of Medicine,

Harvard Medical School

Physician and Emeritus Chief, Division of Infectious Diseases,

Massachusetts General Hospital

(IDSA President 2015)

Mario Caturegli, MD

Professor of Pathology, Endocrinology, and Immunology

Johns Hopkins University Schools of Medicine and Public Health

Johns Hopkins University

Peter V. Chin-hong, MD

Professor of medicine

Associate dean for regional campuses

Director transplant and immunocompromised host infectious disease program

UCSF

Barry Coller, MD

David Rockefeller Professor

Physician in Chief

Vice President for Medical Affairs

Rockefeller University

Claudia S. Cohn, MD, PhD

Professor of Laboratory Medicine and Pathology,

Director, Blood Bank Laboratory

Associate Director, Clinical Laboratories

University of Minnesota

Marie Elena Cordisco, MA, NP-C, APRN

Associate Vice President Clinical Trials

Research and Innovation

Danbury CT

Marilou Corpuz, MD

Associate Professor of Medicine

Clinical Director, Infectious Diseases, Wakefield

Albert Einstein College of Medicine and Montefiore Medical Center

Camille Nelson Kotton MD, FIDSA, FAST

Clinical Director, Transplant and Immunocompromised Host Infectious Diseases

Infectious Diseases Division

Massachusetts General Hospital

Associate Professor, Harvard Medical School

Daniel Cruser, MD

Nuvance Health

Vassar Brothers Medical Center,

Poughkeepsie NY

Charlotte Cunningham-Rundles, MD PhD

David S Gottesman Professor

Department of Medicine

Department of Pediatrics

The Prism Immunology Institute

Icahn School of Medicine at Mount Sinai

Carlos Del Rio, MD

Executive Associate Dean, Emory School of Medicine & Grady Health System

Distinguished Professor, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine

Professor, Hubert Department of Global Health, Rollins School of Public Health

Co-Director, Emory Center for AIDS Research

Co-PI, Emory-CDC HIV Clinical Trials Unit and the Emory Vaccine and Treatment Evaluation Unit

President IDSA

Michael S. Diamond, MD, PhD

The Herbert S. Gasser Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology

M. Veronica Dioverti, M.D.

Assistant Professor | SOM DOM Infectious Disease

Transplant and Oncology Infectious Diseases

Johns Hopkins University

Ferric C. Fang, M.D.

Professor of Laboratory Medicine and Pathology, and Microbiology

Adjunct Professor of Medicine (Infectious Diseases)

Director, Harborview Medical Center Clinical Microbiology Laboratory

University of Washington School of Medicine

Daniel E. Ford MD, MPH

Director, Johns Hopkins Institute for Clinical and Translational Research

Professor of Medicine

Johns Hopkins School of Medicine

Donald Forthal, MD

Professor of Medicine and Molecular Biology and Biochemistry

Center for Virus Research

Chief, Division of Infectious Diseases

University of California, Irvine School of Medicine

Vance Fowler, MD

Florence McAlister Distinguished Professor of Medicine

Professor of Medicine

Duke University

Yuriko Fukuta, MD, PhD

Assistant Professor

Department of Medicine

Section of Infectious Diseases

Baylor College of Medicine

Ravindra Ganesh, MBBS, MD

Assistant Professor of Medicine

Division of General Internal Medicine

Mayo Clinic

Rochester, MN

Neil Gaffin, MD

Ridgewood Infectious Disease Associates

947 Linwood Avenue, Suite 2e

Ridgewood, NJ 07450

Jonathan M. Gerber, MD

Professor of Medicine

Chief, Hematology & Oncology

Director, Cancer Center

Eleanor Eustis Farrington Chair in Cancer Research

UMass Chan Medical School & UMass Memorial Health

Benjamin Greenblatt, MD

Chairman Department of Emergency Medicine

Norwalk Hospital

Norwalk, CT

Neil Greenspan, MD, PhD

Professor

Department of Pathology, School of Medicine

Case Western Reserve University

Amita Gupta, MD, MHS, FIDSA

Dr. Florence Sabin Professor of Infectious Diseases

Chief, Division of Infectious Diseases

Professor of Medicine and International Health

Faculty co-Chair, Johns Hopkins Gupta-Klinsky India Institute

Johns Hopkins University

Kelly Gebo MD, MPH

Professor of Medicine

Johns Hopkins School of Medicine

Inessa Gendlina, MD, PhD

Assistant Professor

Albert Einstein College of Medicine and Montefiore Medical Center

Anne A. Gershon, M.D.

Professor

Department of Pediatrics

Columbia University Vagelos College of P&S

630 West 168th Street, New York, NY10032

(IDSA President 2009)

Dan Hanley, MD

Division Director, Brain Injury Outcomes

Professor of Neurology

Johns Hopkins School of Medicine

Laura Hammitt, MD

Director of Infectious Disease Programs

Center for Indigenous Health

Johns Hopkins Bloomberg School of Public Health

Baltimore, MD

Sarah P. Hammond, MD

Director of Hematology/Oncology Infectious Diseases

Division of Infectious Diseases

Massachusetts General Hospital

Assistant Professor of Medicine

Harvard Medical School

Sonya Heath, MD

Professor of Medicine

University of Alabama @ Birmingham

Birmingham, AL

Vagish Hemmige, MD

Albert Einstein College of Medicine and Montefiore Medical Center

Tobias M. Hohl, MD, PhD

Chief, Infectious Disease Service

Memorial Sloan Kettering Hospital

William Hartman, MD, PhD

Associate Professor

Department of Anesthesiology

University of Wisconsin

Moises A. Huaman, MD MSc

Associate Professor of Medicine

Co-PI, Infectious Diseases Research Unit

University of Cincinnati College of Medicine

Cincinnati, OH

W. Charles Huskins, M.D., M.Sc., FSHEA, FPIDS, FIDSA, FAA

Consultant, Division of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine, Mayo Clinic

Vice Chair of Quality, Mayo Clinic Children’s Center

Professor of Pediatrics, Mayo Clinic College of Medicine and Science

Peter Hotez, MD, PhD, DSc (hon), FASTMH, FAAP

Texas Children’s Hospital: Endowed Chair of Tropical Pediatrics

Co-Director, Texas Children’s Hospital Center for Vaccine Development

Dean, National School of Tropical Medicine

Professor, Departments of Pediatrics, Molecular Virology & Microbiology

Baylor College of Medicine

Justin E. Juskewitch, MD, PhD

Senior Associate Consultant – Division of Transfusion Medicine

Medical Director, Components Laboratory

Associate Medical Director, Donor Services

Associate Program Director, Clinical Informatics Fellowship

Assistant Professor of Laboratory Medicine & Pathology

Department of Laboratory Medicine & Pathology

Mayo Clinic, Rochester, MN

Sabra Klein, PhD

Professor

Johns Hopkins School of Public Health

Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FIDSA, FAAM, FAAAS

Robert C Hickey Chair in Clinical Care

Deputy Head, Division of Internal Medicine

Karen Lane, CCRP

Assistant Professor of Neurology

Deputy Director,

BIOS Clinical Trials Coordinating Center

Department of Neurology

Johns Hopkins University School of Medicine

Adam C. Levine, MD, MPH, FACEP

Professor of Emergency Medicine and Health Services, Policy & Practice

Chief, Division of Global Emergency Medicine

Brown University Alpert Medical School and School of Public Health

Providence RI

W. Ian Lipkin, MD

John Snow Professor of Epidemiology and Director

Center for Infection and Immunity

Mailman School of Public Health

Professor of Pathology and Neurology

College of Physicians & Surgeons

Columbia University

Anne Liu, MD

Clinical Associate Professor, Pediatrics – Immunology and Allergy

Stamford University.

David M. Margolis, MD

Sarah Graham Keenan Distinguished Professor of Medicine, Microbiology & Immunology, Epidemiology

Director, UNC HIV Cure Center

University of North Carolina at Chapel Hill

Barry Meisenberg, MD

Chair Department of Medicine

Medical Director Research Institute

Luminis Health

Annapolis, MD

Giselle Mosnaim, MD, MS,

Division of Allergy and Immunology

Department of Medicine

NorthShore University Health System

Chicago, IL

Megan Morales, MD

Medical Director, Transplant Infectious Diseases

Assistant Professor

Virginia Commonwealth University, Richmond, VA

Eleftherios Mylonakis, MD, PhD, FIDSA

Chair, Department of Medicine

Charles and Anne Duncan Presidential Distinguished Chair

Professor of Medicine, Houston Methodist Academic Institute

Full Member, Houston Methodist Research Institute

Houston Methodist Hospital

James P. Musser, MD, PhD

Chair, Department of Pathology & Genomic Medicine

Fondren Presidential Distinguished Chair, Research Institute

Professor of Pathology and Genomic Medicine, Academic Institute

Director, Center for Infectious Diseases Research

Director, Center for Molecular & Translational Human Infectious Diseases Research

Houston Methodist

Weill Cornell Medical College

Joshua D. Nosanchuk, MD

Professor, Medicine and Microbiology & Immunology

Senior Associate Dean

Albert Einstein College of Medicine

Max O'Donnell MD, MPH

Florence Irving Associate Professor of Medicine

Division of Pulmonary, Allergy, and Critical Care Medicine, & Department of Epidemiology

Columbia University Medical Center

Kevin Oei, D.O.

Principle Investigator

Ascada Research

Fullerton, CA

Mila Ortigoza MD, PhD

Assistant Professor

NYU Langone Medical Center

Luis Ostrosky-Zeichner MD, FACP, FIDSA, FSHEA, CMQ

Professor and Memorial Hermann Endowed Chair,

McGovern Medical School

Stuart Packer, MD

Clinical Director Medical Oncology

Albert Einstein College of Medicine and Montefiore Medical Center

Suchitra Pandey, MD

Clinical Associate Professor, Department of Pathology

Stanford University School of Medicine

Chief Medical Officer, Stanford Blood Center

Palo Alto, CA

Bela Patel, M.D., FCCP, FCCM

Graham Distinguished University Chair

Vice Dean of Healthcare Quality

Vice Chair of Medicine for Memorial Hermann

Division Director of Critical Care Medicine

Interim Director of Pulmonary and Sleep Medicine

Distinguished Teaching Professor of The University of Texas System

Professor of Medicine

Houston, TX

James Paxton, MD

Assistant Professor - Clinical Scholar

Reseach Director – DRH

Wayne State University

Detroit, MI

Joann Petrini PhD, MPH

Brookfield, Connecticut

John Perfect, MD

James B. Duke Distinguished Professor of Medicine

Professor of Medicine

Chief, Division of Infectious Diseases

Professor in Molecular Genetics and Microbiology

Duke University

Yoram Puius, MD, PhD

Associate Professor of Medicine

Albert Einstein College of Medicine and Montefiore Medical Center

Jay S. Raval, M.D.

Associate Professor

Vice Chair for Clinical Affairs

Director, Transfusion Medicine and Therapeutic Pathology

University of New Mexico Department of Pathology

Albuquerque, NM USA

Rita A. Reik, MD

Chief Medical Officer

OneBlood, Inc.

10100 Dr. MLK Jr St N

St. Petersburg, FL 33716

Louis B. Rice, M.D.

Joukowsky Family Professor and Chair

Department of Medicine

Warren Alpert Medical School of Brown University

Juan G. Ripoll, MD

Cardiothoracic Anesthesiologist and Intensivist

Mayo Clinic

Rochester, MN

Heather Root, MD

Assistant Professor

Albert Einstein College of Medicine and Montefiore Medical Center

Michael Ross, MD

Professor

Division Chief, Nephrology

Albert Einstein College of Medicine and Montefiore Medical Center

Eric Salazar, MD, PhD

Associate Professor

UT Health San Antonio

Cynthia L. Sears, M.D.

Bloomberg Kimmel Professor of Immunotherapy

Professor of Medicine, Oncology & Molecular Microbiology and Immunology

Johns Hopkins University School of Medicine

(IDSA President 2019)

Jonathon (Jack) Senefeld, Ph.D.

Assistant Professor

Department of Anesthesiology and Perioperative Medicine

Mayo Clinic Rochester

Aarthi Shenoy, MD

Hematology/Oncology

Washington Hospital Center

Washington DC

Samuel Silverstein, MD

Emeritus John C. Dalton Professor of Physiology & Cellular Biophysics, and Professor of Medicine

Columbia University

Atika Singh, OMS I

Pacific Northwest University of Health Sciences

Yakima, WA

David Sullivan, MD

Professor

Department of Microbiology and Immunology

Johns Hopkins School of Public Health

Baltimore, MD

Ralph Tayyar, MD

Transplant Infectious Diseases Fellow

Stamford University

Aaron Tobian, MD

Professor of Pathology, Medicine and Epidemiology

Director, Transfusion Medicine Division

Deputy Director for Clinical Affairs, Department of Pathology

Johns Hopkins School of Medicine

Michael Thompson, MD, PhD

Vice President of Clinical Partnerships at Tempus Labs

Milwaukee, WI

Eric Topol, MD

Professor, Molecular Medicine and EVP Scripps Research

Founder and Director, SRTI

Julian A. Torres, MD

Assistant Professor

Albert Einstein School of Medicine and Montefiore Medical Center

Helen Tsai, MD

Assistant professor

Albert Einstein College of Medicine and Montefiore Medical Center

Sidna Tulledge-Scheitel, MD MPH

Medical Director Mayo Clinic Midwest COVID-19 Ambulatory Care Team

David van Duin, MD, PhD

Professor of Medicine

Director, Immunocompromised Host Infectious Diseases Section

Department of Medicine

University of North Carolina

Chapel Hill, NC

Jeremy L. Warner MD, MS, FAMIA, FASCO

Professor of Medicine at Brown University

Director, Center for Clinical Cancer Informatics and Data Science (CCIDS)

Director, COVID-19 and Cancer Consortium (CCC19) Research Coordinating Center

Deputy Editor, JCO Clinical Cancer Informatics

Deputy Editor, HemOnc.org

Gregory Weston, MD MSCR

Associate Professor of Medicine

Interim Hospital Epidemiologist

Albert Einstein College of Medicine and Montefiore Medical Center

Richard Whitley, MD

Distinguished Professor

Loeb Scholar in Pediatrics

Professor of Pediatrics, Microbiology,

Medicine and Neurosurgery

Heersink School of Medicine

University of Alabama at Birmingham

(IDSA President 2010)

R. Scott Wright, MD

Professor of Medicine

Mayo Clinic, Rochester

Anusha Yarava, PharmD, MPH

IDS-Pharmacist Manager/Biostatistician

BIOS Clinical Trials Coordinating Center

Department of Neurology

Johns Hopkins University School of Medicine

Baltimore, MD

Hyunah Yoon, MD

Albert Einstein College of Medicine and Montefiore Medical Center

Barry S. Zingman, MD

Professor

Medical Director, AIDS Center and Jacobs Family Pride Wellness Center of Montefiore Nyack Hospital, Albert Einstein College of Medicine and Montefiore Medical Center

1. Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al.COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023;6(1):e2250647.

2. Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, et al.Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer. 2023;4(1):96-107.

3. Bloch EM, Focosi D, Shoham S, Senefeld J, Tobian AAR, Baden LR, et al.Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19. Clin Infect Dis. 2023.

4. Moog R. COVID 19 convalescent plasma: Is there still a place for CCP? Transfus Apher Sci. 2023:103680.

5. Schrezenmeier H, Hoffmann S, Hofmann H, Appl T, Jahrsdörfer B, Seifried E, et al.Immune Plasma for the Treatment of COVID-19: Lessons Learned so far. Hamostaseologie. 2023;43(1):67-74.

6. Senefeld JW, Gorman EK, Johnson PW, Moir ME, Klassen SA, Carter RE, et al.Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma A Systematic review and meta-analysis. medRxiv. 2023:2023.01.11.23284347.